Biotech Values

[DewDiligence]

>It looks like this data could have contributed to the IDIX swoon which started in March, depending on how widely it may have leaked prior to publication.<

That’s quite plausible, IMO, because the dose adjustment in March never seemed as bad as the market’s reaction to it.

Yet IDIX and NVS are moving ahead as though no dose escalation on account of ribavirin will ever be needed. Hence, investors who may have acted on a leak of this publication could have done the right thing for the wrong reason by turning bearish several months ago.